Author of 1 Presentation
SS 1.2 - Prevalence of significant hepatic fibrosis using MR elastography in a health check-up clinic population
Abstract
Purpose
Using MR elastography (MRE), we investigated the prevalence of significant fibrosis in a community-based cohort.
Material and methods
From January 2015 to May 2018, 2,170 participants receiving a health examination at our institution were enrolled in this study. All participants underwent MR chemical shift technique and MRE to assess liver fat and fibrosis, respectively. We also conducted subgroup analyses for participants with nonalcoholic fatty liver disease (NAFLD), metabolic syndrome, and diabetes mellitus (DM). For generalization, sex- and age-standardized prevalence estimates of hepatic fibrosis and fatty liver were also calculated based on the Korean Statistical Information Service (KOSIS) during 2015-2018.
Results
The prevalence of F2 (≥3.0 kPa) and F3 fibrosis (≥3.6 kPa) in the overall cohort was 5.1% and 1.3%, respectively (sex- and age-adjusted prevalence of 3.8% and 1.3%). NAFLD prevalence (>5% fat fraction) was 20.8% in the average-risk population (after excluding alcohol use and viral hepatitis), and the prevalence of significant and advanced fibrosis in NAFLD participants was 7.5% and 1.1%, respectively. The prevalence of DM was 7.7% in the overall cohort, with significant fibrosis in 13.7% and advanced fibrosis in 4.8%. In participants with fatty liver (of any etiology) plus diabetes, 27.5% had ≥F2 and 7.2% ≥F3. Multivariate analyses indicated that older age, insulin, diabetes, and fatty liver were independently associated with significant fibrosis.
Conclusion
In a health check-up clinic setting, the prevalence of significant and advanced fibrosis was 5.1% and 1.3% in (sex- and age-adjusted prevalence of 3.8% and 1.3%, respectively) and increased three- to fourfold with diabetes.
Presenter of 1 Presentation
SS 1.2 - Prevalence of significant hepatic fibrosis using MR elastography in a health check-up clinic population
Abstract
Purpose
Using MR elastography (MRE), we investigated the prevalence of significant fibrosis in a community-based cohort.
Material and methods
From January 2015 to May 2018, 2,170 participants receiving a health examination at our institution were enrolled in this study. All participants underwent MR chemical shift technique and MRE to assess liver fat and fibrosis, respectively. We also conducted subgroup analyses for participants with nonalcoholic fatty liver disease (NAFLD), metabolic syndrome, and diabetes mellitus (DM). For generalization, sex- and age-standardized prevalence estimates of hepatic fibrosis and fatty liver were also calculated based on the Korean Statistical Information Service (KOSIS) during 2015-2018.
Results
The prevalence of F2 (≥3.0 kPa) and F3 fibrosis (≥3.6 kPa) in the overall cohort was 5.1% and 1.3%, respectively (sex- and age-adjusted prevalence of 3.8% and 1.3%). NAFLD prevalence (>5% fat fraction) was 20.8% in the average-risk population (after excluding alcohol use and viral hepatitis), and the prevalence of significant and advanced fibrosis in NAFLD participants was 7.5% and 1.1%, respectively. The prevalence of DM was 7.7% in the overall cohort, with significant fibrosis in 13.7% and advanced fibrosis in 4.8%. In participants with fatty liver (of any etiology) plus diabetes, 27.5% had ≥F2 and 7.2% ≥F3. Multivariate analyses indicated that older age, insulin, diabetes, and fatty liver were independently associated with significant fibrosis.
Conclusion
In a health check-up clinic setting, the prevalence of significant and advanced fibrosis was 5.1% and 1.3% in (sex- and age-adjusted prevalence of 3.8% and 1.3%, respectively) and increased three- to fourfold with diabetes.
Author of 1 Presentation
SS 1.2 - Prevalence of significant hepatic fibrosis using MR elastography in a health check-up clinic population (ID 268)
Abstract
Purpose
Using MR elastography (MRE), we investigated the prevalence of significant fibrosis in a community-based cohort.
Material and methods
From January 2015 to May 2018, 2,170 participants receiving a health examination at our institution were enrolled in this study. All participants underwent MR chemical shift technique and MRE to assess liver fat and fibrosis, respectively. We also conducted subgroup analyses for participants with nonalcoholic fatty liver disease (NAFLD), metabolic syndrome, and diabetes mellitus (DM). For generalization, sex- and age-standardized prevalence estimates of hepatic fibrosis and fatty liver were also calculated based on the Korean Statistical Information Service (KOSIS) during 2015-2018.
Results
The prevalence of F2 (≥3.0 kPa) and F3 fibrosis (≥3.6 kPa) in the overall cohort was 5.1% and 1.3%, respectively (sex- and age-adjusted prevalence of 3.8% and 1.3%). NAFLD prevalence (>5% fat fraction) was 20.8% in the average-risk population (after excluding alcohol use and viral hepatitis), and the prevalence of significant and advanced fibrosis in NAFLD participants was 7.5% and 1.1%, respectively. The prevalence of DM was 7.7% in the overall cohort, with significant fibrosis in 13.7% and advanced fibrosis in 4.8%. In participants with fatty liver (of any etiology) plus diabetes, 27.5% had ≥F2 and 7.2% ≥F3. Multivariate analyses indicated that older age, insulin, diabetes, and fatty liver were independently associated with significant fibrosis.
Conclusion
In a health check-up clinic setting, the prevalence of significant and advanced fibrosis was 5.1% and 1.3% in (sex- and age-adjusted prevalence of 3.8% and 1.3%, respectively) and increased three- to fourfold with diabetes.
Presenter of 1 Presentation
SS 1.2 - Prevalence of significant hepatic fibrosis using MR elastography in a health check-up clinic population (ID 268)
Abstract
Purpose
Using MR elastography (MRE), we investigated the prevalence of significant fibrosis in a community-based cohort.
Material and methods
From January 2015 to May 2018, 2,170 participants receiving a health examination at our institution were enrolled in this study. All participants underwent MR chemical shift technique and MRE to assess liver fat and fibrosis, respectively. We also conducted subgroup analyses for participants with nonalcoholic fatty liver disease (NAFLD), metabolic syndrome, and diabetes mellitus (DM). For generalization, sex- and age-standardized prevalence estimates of hepatic fibrosis and fatty liver were also calculated based on the Korean Statistical Information Service (KOSIS) during 2015-2018.
Results
The prevalence of F2 (≥3.0 kPa) and F3 fibrosis (≥3.6 kPa) in the overall cohort was 5.1% and 1.3%, respectively (sex- and age-adjusted prevalence of 3.8% and 1.3%). NAFLD prevalence (>5% fat fraction) was 20.8% in the average-risk population (after excluding alcohol use and viral hepatitis), and the prevalence of significant and advanced fibrosis in NAFLD participants was 7.5% and 1.1%, respectively. The prevalence of DM was 7.7% in the overall cohort, with significant fibrosis in 13.7% and advanced fibrosis in 4.8%. In participants with fatty liver (of any etiology) plus diabetes, 27.5% had ≥F2 and 7.2% ≥F3. Multivariate analyses indicated that older age, insulin, diabetes, and fatty liver were independently associated with significant fibrosis.
Conclusion
In a health check-up clinic setting, the prevalence of significant and advanced fibrosis was 5.1% and 1.3% in (sex- and age-adjusted prevalence of 3.8% and 1.3%, respectively) and increased three- to fourfold with diabetes.